

8/23/04

17W



EXPRESS MAIL NO. EV449562682US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Orest W. Blaschuk et al.  
Application No. : 10/759,507  
Filed : January 16, 2004  
For : METHODS FOR DIAGNOSIS AND EVALUATING CANCER

Art Unit : 1613  
Docket No. : 100086.407C11  
Date : August 19, 2004

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Jeffrey E. Hundley, Ph.D., Patent Agent  
Registration No. 42,676

JEH:ljt

Enclosures:

Postcard  
Transmittal Form  
Form PTO-1449 (9 Sheets)  
Cited References (81)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

\508788

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,585,351	12/17/96	Ranscht	514	12	
	AB	5,597,725	01/28/97	Suzuki	435	328	
	AC	5,610,281	03/11/97	Brenner et al.	530	388.85	
	AD	5,639,634	06/17/97	Suzuki	435	69.1	
	AE	5,643,781	07/01/97	Suzuki	435	325	
	AF	5,646,250	07/08/97	Suzuki	530	350	
	AG	5,663,300	09/02/97	Suzuki	530	350	
	AH	5,708,143	01/13/98	Suzuki	530	350	
	AI	5,811,514	09/22/98	Bard et al.	530	324	
	AJ	5,869,683	02/09/99	Takeshita et al.	536	23.5	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AK	GB 2 282 379 A	04/05/95	United Kingdom		
	AL	WO 91/04745	04/18/91	WIPO		
	AM	WO 94/11401	05/26/94	WIPO		
	AN	WO 96/27387	09/12/96	WIPO		
	AO	WO 97/38011	10/16/97	WIPO		

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Albelda et al., "Adhesion Molecules and Inflammatory Injury," <i>FASEB J.</i> 8(8): 504-512, May 1994.
	AQ	Bangma et al., "The Value of Screening Tests in the Detection of Prostate Cancer. Part I: Results of a Retrospective Evaluation of 1726 Men," <i>Urology</i> 46(6): 773-778, 1995.
	AR	Berndorff et al., "Liver-Intestine Cadherin: Molecular Cloning and Characterization of a Novel Ca <sup>2+</sup> -dependent Cell Adhesion Molecule Expressed in Liver and Intestine," <i>The Journal of Cell Biology</i> 125(6): 1353-1369, June 1994.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	5,916,771	06/29/99	Hori et al.	435	69.6	
	BB	6,031,072	02/29/00	Blaschuk et al.	530	317	
	BC	6,060,595	05/09/00	Scaglioni et al.	536	23.72	
	BD	6,083,713	07/04/00	Manly et al.	435	69.1	
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BK	WO 98/02452	01/22/98	WIPO		
	BL	WO 98/25946	06/18/98	WIPO		
	BM	WO 00/02917	01/20/00	WIPO		
	BN					
	BO					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	BP	Blaschuk et al., "E-cadherin, estrogens and cancer: is there a connection?," <i>The Canadian Journal of Oncology</i> 4(4): 291-301, November 1994.
	BQ	Bussemakers et al., "The role of OB-cadherin in human prostate cancer," in <i>Proceedings of the American Association for Cancer Research, Vol. 39</i> , New Orleans, LA, March, 1998, page 500.
	BR	Caveda, L. et al., "Inhibition of Cultured Cell Growth by Vascular Endothelial Cadherin (Cadherin-5/VE-Cadherin)," <i>Journal of Clinical Investigation</i> 98(4): 886-893, August 1996.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
CB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CC	Doherty and Walsh, "CAM-FGF Receptor Interactions: A Model for Axonal Growth," <i>Molecular and Cellular Neuroscience</i> 8: 99-111, 1996.
CD	Doherty and Walsh, "Signal transduction events underlying neurite outgrowth stimulated by cell adhesion molecules," <i>Current Opinion in Neurobiology</i> 4: 49-55, 1994.
CE	Edgington, "How Sweet It Is: Selectin-Mediating Drugs," <i>Bio/Technology</i> 10(4): 383-389, April 1992.
CF	Fredette and Ranscht, "T-Cadherin Expression Delineates Specific Regions of the Developing Motor Axon-Hindlimb Projection Pathway," <i>The Journal of Neuroscience</i> 14(12): 7331-7346, December 1994.
CG	Getsios et al., "Regulated Expression of Cadherin-6 and Cadherin-11 in the Glandular Epithelial and Stromal Cells of the Human Endometrium," <i>Developmental Dynamics</i> 211: 238-247, 1998.
CH	Griffiths et al., "Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence," <i>Br. J. Cancer</i> 74: 579-584, 1996.
CI	Grillner and Matsushima, "The Neural Network Underlying Locomotion in Lamprey - Synaptic and Cellular Mechanisms," <i>Neuron</i> 7: 1-15, July 1991.
CJ	Hall et al., "Review: A Role for the FGF Receptor in the Axonal Growth Response Stimulated by Cell Adhesion Molecules?," <i>Cell Adhesion and Communication</i> 3: 441-450, 1996.
CK	Huber, P. et al., "Genomic Structure and Chromosomal Mapping of the Mouse VE-Cadherin Gene ( <i>Cdh5</i> )," <i>Genomics</i> 32: 21-28, 1996.
CL	Inoue et al., "Cadherin-6 in the Developing Mouse Brain: Expression Along Restricted Connection Systems and Synaptic Localization Suggest a Potential Role in Neuronal Circuitry," <i>Developmental Dynamics</i> 211: 338-351, April 1998.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
DB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DC	Kahan, "Immunosuppressive Therapy," <i>Current Opinion in Immunology</i> 4(5): 553-560, October 1992.
DD	Katayama et al., "Soluble E-cadherin fragments increased in circulation of cancer patients," <i>Br. J. Cancer</i> 69: 580-585, 1994.
DE	Kawamura et al., "cDNA Cloning and Expression of a Novel Human Desmocollin," <i>The Journal Of Biological Chemistry</i> 269(42): 26295-26302, October 1994.
DF	Kimura, Y. et al., "Cadherin-11 Expressed in Association with Mesenchymal Morphogenesis in the Head, Somite, and Limb Bud of Early Mouse Embryos," <i>Developmental Biology</i> 169: 347-358, 1995.
DG	King et al., "Cloning of the cDNA (DSC1) Coding for Human Type 1 Desmocollin and Its Assignment to Chromosome 18," <i>Genomics</i> 18: 185-194, 1993.
DH	King et al., "The Desmocollins of Human Foreskin Epidermis: Identification and Chromosomal Assignment of a Third Gene and Expression Patterns of the Three Isoforms," <i>J Invest Dermatol</i> 105: 314-321, 1995.
DI	Klopfenstein et al., "Increased N-cadherin mediated adhesion does not reduce invasion of Rous sarcoma virus-transformed astrocyte-like WC5 cells," <i>Proceedings of the American Association for Cancer Research</i> 34:33, March 1993.
DJ	Knudsen et al., "Interaction of alpha-actinin with the cadherin/catenin cell-cell adhesion complex via alpha-catenin," <i>J. Cell Biol.</i> 130(1):67-77, July 1995.
DK	Koch et al., "Complete amino acid sequence of the epidermal desmoglein precursor polypeptide and identification of a second type of desmoglein gene," <i>European Journal of Cell Biology</i> 55: 200-208, 1991.
DL	Kogan et al., "A Single Amino Acid Residue Can Determine the Ligand Specificity of E-selectin," <i>The Journal of Biological Chemistry</i> 270(23):14047-14055, June 9, 1995.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
EA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
EB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EC	Kohmura et al., "Diversity Revealed by a Novel Family of Cadherins Expressed in Neurons at a Synaptic Complex," <i>Neuron</i> 20: 1137-1151, June 1998.
ED	Kools, P.F.J. et al., "Expression in mesenchymal tumors of alternative cadherin-11 transcripts encoding truncated adhesion molecules: a mechanism for acquiring invasive properties?" <i>Clinical &amp; Experimental Metastasis</i> 14(Suppl.1): 52-53, September 1996.
EE	Loric et al., "Enhanced Detection of Hematogenous Circulating Prostatic Cells in Patients with Prostate Adenocarcinoma by Using Nested Reverse Transcription Polymerase Chain Reaction Assay Based on Prostate-Specific Membrane Antigen," <i>Clin. Chem.</i> 41(12): 1698-1704, 1995.
EF	Lutz et al., "Antibody Recognition of Peptide Sequences from the Cell-Cell Adhesion Proteins: N- and E-cadherins," <i>Peptide Research</i> 9(5): 233-239, 1996.
EG	Matsuoka et al., "Recognition of Ovarian Cancer Antigen CA125 by Murine Monoclonal Antibody Produced by Immunization of Lung Cancer Cells," <i>Cancer Res.</i> 47: 6335-6340, December 1, 1987.
EH	Matsuyoshi and Imamura, "Multiple Cadherins Are Expressed in Human Fibroblasts," <i>Biochemical And Biophysical Research Communications</i> 235: 355-358, 1997.
EI	Mulders et al., "Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor marker," <i>Eur. J. Surg. Oncol.</i> 16: 37-41, 1990.
EJ	Munro and Blaschuk, "A Comprehensive Survey of the Cadherins Expressed in the Testes of Fetal, Immature, and Adult Mice Utilizing the Polymerase Chain Reaction," <i>Biology Of Reproduction</i> 55: 822-827, 1996.
EK	Munro and Blaschuk, <i>In: Cell Adhesion and Invasion in Cancer Metastasis</i> , P. Brodt (ed.), RG Landes Co., Austin, Texas, 1996, Chapter 3, "The Structure, Function and Regulation of Cadherins," pp. 17-34.
EL	Munro et al., "Characterization of Cadherins Expressed by Murine Thymocytes," <i>Cellular Immunology</i> 169: 309-312, 1996.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FA						

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
FB					

**OTHER ART** (Including Author, Title, Date, Pertinent Pages, Etc.)

FC	Munro, S.B. et al., "E-Cadherin and OB-Cadherin mRNA in Normal Human Colon and Colon Carcinoma," <i>Experimental and Molecular Pathology</i> 62(2): 118-122, April 1995.
FD	Nagashima et al., "Invasion properties in malignant gliomas_ expression of N-cadherin mRNA in gliomas," <i>Proceedings of the American Association for Cancer Research</i> 37:68, March 1996.
FE	Nakagawa and Takeichi, "Neural crest cell-cell adhesion controlled by sequential and subpopulation-specific expression of novel cadherins," <i>Development</i> 121: 1321-1332, 1995.
FF	Navarro et al., "Differential Localization of VE- and N-Cadherins in Human Endothelial Cells: VE-Cadherin Competes with N-Cadherin for Junctional Localization," <i>The Journal of Cell Biology</i> 140(6): 1475-1484, March 23, 1998.
FG	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. Le Grand (eds.), Birkhäuser, Boston, pp. 491-495, 1994.
FH	Okazaki et al., "Molecular Cloning and Characterization of OB-cadherin, a New Member of Cadherin Family Expressed in Osteoblasts," <i>The Journal of Biological Chemistry</i> 269(16): 12092-12098, April 22, 1994.
FI	Parker et al., "Desmosomal Glycoproteins II and III. Cadherin-Like Junctional Molecules Generated By Alternative Splicing," <i>The Journal of Biological Chemistry</i> 266(16): 10438-10445, January 1991.
FJ	Pishvaian, M.J. et al., "Cadherin-11 Is Expressed in Invasive Breast Cancer Cell Lines," <i>Cancer Research</i> 59: 947-952, February 15, 1999.
FK	Ranscht and Bronner-Fraser, "T-cadherin expression alternates with migrating neural crest cells in the trunk of the avian embryo," <i>Development</i> 111: 15-22, January 1991.
FL	Ranscht and Dours-Zimmermann, "T-Cadherin, a Novel Cadherin Cell Adhesion Molecule in the Nervous System Lacks the Conserved Cytoplasmic Region," <i>Neuron</i> 7: 391-402, September 1991.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	GB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GC	Redies and Takeichi, "Cadherins in the Developing Central Nervous System: An Adhesive Code for Segmental and Functional Subdivisions," <i>Developmental Biology</i> 180: 413-423, 1996.
	GD	Rozdzinski <i>et al.</i> , Antiinflammatory Effects in Experimental Meningitis of Prokaryotic Peptides that Mimic Selectins," <i>J. Infect. Dis.</i> 168:1422-1428, 1993.
	GE	Rustin <i>et al.</i> , "Defining Response of Ovarian Carcinoma to Initial Chemotherapy According to Serum CA 125," <i>J. Clin. Oncol.</i> 14(5): 1545-1551, May 1996.
	GF	Sacristán <i>et al.</i> , "T-Cadherin 2: Molecular Characterization, Function in Cell Adhesion, and Coexpression With T-Cadherin and N-Cadherin," <i>Journal of Neuroscience Research</i> 34: 664-680, 1993.
	GG	Saffell <i>et al.</i> , "Expression of a Dominant Negative FGF Receptor Inhibits Axonal Growth and FGF Receptor Phosphorylation Stimulated by CAMs," <i>Neuron</i> 18: 231-242, 1997.
	GH	Sano <i>et al.</i> , "Protocadherins: a large family of cadherin-related molecules in central nervous system," <i>The EMBO Journal</i> 12(6): 2249-2256, 1993.
	GI	Shibata <i>et al.</i> , "Identification of Human Cadherin-14, a Novel Neurally Specific Type II Cadherin, by Protein Interaction Cloning," <i>The Journal Of Biological Chemistry</i> 272(8): 5236-5240, February 21, 1997.
	GJ	Shibata <i>et al.</i> , "Simultaneous expression of cadherin-11 in signet-ring cell carcinoma and stromal cells of diffuse-type gastric cancer," <i>Cancer Letters</i> 99: 147-153, 1996.
	GK	Shimazui <i>et al.</i> , "Complex Cadherin Expression in Renal Cell Carcinoma," <i>Cancer Research</i> 56: 3234-3237, July 15, 1996.
	GL	Shimoyama <i>et al.</i> , "Isolation and Sequence Analysis of Human Cadherin-6 Complementary DNA for the Full Coding Sequence and Its Expression in Human Carcinoma Cells," <i>Cancer Research</i> 55: 2206-2211, May 15, 1995.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. <b>100086.407C11</b>	APPLICATION NO. <b>10/759,507</b>	
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				APPLICANTS <b>Orest W. Blaschuk et al.</b>		
				FILING DATE <b>January 16, 2004</b>		GROUP ART UNIT <b>1613</b>
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
	HA					
<b>FOREIGN PATENT DOCUMENTS</b>						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	HB					
<b>OTHER ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
	HC	Shimoyama et al., "Molecular Cloning and Characterization of a Novel Human Classic Cadherin Homologous with Mouse Muscle Cadherin," <i>The Journal of Biological Chemistry</i> 273(16): 10011-10018, April 17, 1998.				
	HD	Simonneau et al., "Cadherin 11 Expression Marks the Mesenchymal Phenotype: Towards New Functions for Cadherins?," <i>Cell Adhesion and Communication</i> 3: 115-130, 1995.				
	HE	Slootstra et al., "Structural Aspects of Antibody-Antigen Interaction Revealed Through Small Random Peptide Libraries," <i>Molecular Diversity I</i> : 87-96, 1995.				
	HF	Sugimoto et al., "Molecular Cloning and Characterization of a Newly Identified Member of the Cadherin Family, PB-cadherin," <i>The Journal Of Biological Chemistry</i> 271(19): 11548-11556, May 10, 1996.				
	HG	Suzuki et al., "Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue," <i>Cell Regulation</i> 2: 261-270, April 1991.				
	HH	Taber's Cyclopedic Medical Dictionary, 17 <sup>th</sup> Ed., F.A. Davis Company, Philadelphia, 1993, pg. 1016.				
	HI	Tanihara et al., "Cloning of Five Human Cadherins Clarifies Characteristic Features of Cadherin Extracellular Domain and Provides Further Evidence for Two Structurally Different Types of Cadherin," <i>Cell Adhesion and Communication</i> 2: 15-26, 1994.				
	HJ	The Merck Manual of Diagnosis and Therapy, 16 <sup>th</sup> ED., Berkow, R. et al. (eds.), Merck Research Laboratories, Rahway, NJ, 1992, pgs. 1264-1265.				
	HK	Tkachuk et al., "Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin," <i>FEBS Letters</i> 421: 208-212, 1998.				
	HL	Tsutsui et al., "Expression of Cadherin-Catenin Complexes in Human Leukemia Cell Lines," <i>J. Biochem.</i> 120: 1034-1039, 1996.				
EXAMINER				DATE CONSIDERED		
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MBEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).						

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 100086.407C11	APPLICATION NO. 10/759,507
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)		APPLICANTS Orest W. Blaschuk et al.	
		FILING DATE January 16, 2004	GROUP ART UNIT 1613

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
IA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
IB					

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

IC	Vallin, J. et al., "Xenopus cadherin-11 is expressed in different populations of migrating neural crest cells," <i>Mechanisms of Development</i> 75(1-2): 171-174, July 1998.
ID	Van Den Br�le et al., "Genes Involved in Tumor Invasion and Metastasis are Differentially Modulated by Estradiol and Progesterone in Human Breast-Cancer Cells," <i>Int. J. Cancer</i> 52: 653-657, 1992.
IE	Vestal and Ranscht, "Glycosyl Phosphatidylinositol-anchored T-Cadherin Mediates Calcium-dependent, Homophilic Cell Adhesion," <i>The Journal of Cell Biology</i> 119(2): 451-461, October 1992.
IF	Ward and Mulligan, "Blocking of Adhesion Molecules <i>In Vivo</i> as Anti-Inflammatory Therapy," <i>Therapeutic Immunology</i> 1: 165-171, 1994.
IG	Wheeler et al., "Desmosomal glycoprotein DGI, a component of intercellular desmosome junctions, is related to the cadherin family of cell adhesion molecules," <i>Proc. Natl. Acad. Sci. USA</i> 88: 4796-4800, June 1991.
IH	Wheelock, M.J. et al., "Soluble 80-kd Fragment of Cell-CAM 120/80 Disrupts Cell-Cell Adhesion," <i>Journal of Cellular Biochemistry</i> 34: 187-202, 1987.
II	Williams et al., "Activation of the FGF Receptor Underlies Neurite Outgrowth Stimulated by L1, N-CAM, and N-Cadherin," <i>Neuron</i> 13: 583-594, September 1994.
IJ	
IK	
IL	

EXAMINER	DATE CONSIDERED
----------	-----------------

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).



EXPRESS MAIL NO. EV449562682US

**TRANSMITTAL  
FORM***(To be used for all correspondence  
after initial filing)*

Application Number	10/759,507
Filing Date	January 16, 2004
First Named Inventor	Orest W. Blaschuk
Art Unit	1613
Examiner Name	
Attorney Docket No.	100086.407C11

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement; Form PTO-1449 <input checked="" type="checkbox"/> 81 Cited References <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts under 37 C.F.R. 1.52 or 1.53 <input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address <input type="checkbox"/> Declaration <input type="checkbox"/> Statement under 37 CFR 3.73(b) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund	<input type="checkbox"/> CD(s), Number of CD(s) _____ <input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC ( <i>Appeal Notice, Brief, Reply Brief</i> ) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Additional Enclosure(s) ( <i>please identify below</i> ): _____ _____ _____
--	---	--

Remarks**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Individual Name	Jeffrey E. Hundley, Ph.D., Patent Agent Reg. No. 42,676	Customer Number <b>00500</b>
Signature		
Date	August 19, 2004	

**CERTIFICATE OF TRANSMISSION/MAILING****VIA EXPRESS MAIL**

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

1508787